Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection
- PMID: 20713178
- DOI: 10.1016/j.cgh.2010.06.032
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection
Abstract
Hepatitis C virus (HCV) infections pose a growing challenge to health care systems. Although chronic HCV infection begins as an asymptomatic condition with few short-term effects, it can progress to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death. The rate of new HCV infections is decreasing, yet the number of infected people with complications of the disease is increasing. In the United States, people born between 1945 and 1964 (baby boomers) are developing more complications of infection. Men and African Americans have a higher prevalence of HCV infection. Progression of fibrosis can be accelerated by factors such as older age, duration of HCV infection, sex, and alcohol intake. Furthermore, insulin resistance can cause hepatic steatosis and is associated with fibrosis progression and inflammation. If more effective therapies are not adopted for HCV, more than 1 million patients could develop HCV-related cirrhosis, hepatic decompensation, or HCC by 2020, which will impact the US health care system. It is important to recognize the impact of HCV on liver disease progression and apply new therapeutic strategies.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.Am J Gastroenterol. 2001 Jan;96(1):179-83. doi: 10.1111/j.1572-0241.2001.03374.x. Am J Gastroenterol. 2001. PMID: 11197250
-
Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.Cancer. 2006 Nov 1;107(9):2212-22. doi: 10.1002/cncr.22242. Cancer. 2006. PMID: 17019738
-
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46. Minerva Gastroenterol Dietol. 2005. PMID: 15756144 English, Italian.
-
[Late sequelae of HCV infection].Przegl Epidemiol. 2008;62(4):777-83. Przegl Epidemiol. 2008. PMID: 19209740 Review. Polish.
-
The natural history of hepatitis C viral infection.Semin Gastrointest Dis. 2000 Apr;11(2):54-61. Semin Gastrointest Dis. 2000. PMID: 10803630 Review.
Cited by
-
Global control of hepatitis C: where challenge meets opportunity.Nat Med. 2013 Jul;19(7):850-8. doi: 10.1038/nm.3184. Nat Med. 2013. PMID: 23836235 Free PMC article. Review.
-
Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.PLoS One. 2015 Jun 19;10(6):e0129868. doi: 10.1371/journal.pone.0129868. eCollection 2015. PLoS One. 2015. PMID: 26090666 Free PMC article.
-
Current and future disease progression of the chronic HCV population in the United States.PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013. PLoS One. 2013. PMID: 23704962 Free PMC article.
-
Activation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus.PLoS Pathog. 2015 Nov 20;11(11):e1005264. doi: 10.1371/journal.ppat.1005264. eCollection 2015 Nov. PLoS Pathog. 2015. PMID: 26588843 Free PMC article.
-
Identification of HNRNPK as regulator of hepatitis C virus particle production.PLoS Pathog. 2015 Jan 8;11(1):e1004573. doi: 10.1371/journal.ppat.1004573. eCollection 2015 Jan. PLoS Pathog. 2015. PMID: 25569684 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical